Discuss This Drug

Pralatrexate

CHEBI:CHEBI_71223

Definition

A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.

Chemical Information

Molecular Formula
C23H23N7O5
Molecular Mass
477.47260
Charge
0
SMILES
Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1
InChI
InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1
InChIKey
OGSBUKJUDHAQEA-WMCAAGNKSA-N

Alternative Names

  • (2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid
  • (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid
  • 10-Propargyl-10-deazaaminopterin
  • Folotyn
  • HSDB 7786
  • N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
  • N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid
  • pralatrexate
  • pralatrexato
  • pralatrexatum

Treatment Applications

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:71223
DRON_00010000
662019
oboInOwl#hasDbXref
Wikipedia:Pralatrexate

Additional References

Wikipedia:Pralatrexate

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rdf-schema#range
https://w3id.org/def/predibionto#has_drug_113547
has_treatment
http://purl.obolibrary.org/obo/DOID_1038
owl#annotatedSource
t280273
owl#someValuesFrom
t3020091
core#notation
CHEBI:71223
rxcui
1796425
package_marketing_start_date
17-JUL-13
pharm_class_epc
Folate Analog Metabolic Inhibitor [EPC]
pharm_class
Folate Analog Metabolic Inhibitor [EPC]
active_ingredient_strength
.5 kg/.5kg
manufacturer_name
Fresenius Kabi USA, LLC
active_ingredient_name
PRALATREXATE
package_ndc
47848-045-00
package_description
1 kg in 1 CARTON (47848-045-00)
unii
A8Q8I19Q20
spl_set_id
a5daa583-4965-4564-ad87-41ffe6c08a11
nui
N0000175584
upc
0072893005011
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
662019
oboInOwl#hasDbXref
Wikipedia:Pralatrexate
oboInOwl#id
CHEBI:71223
brand_name
Pralatrexate
brand_name_base
Pralatrexate
generic_name
Pralatrexate
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
listing_expiration_date
20241231
dosage_form
INJECTION
marketing_start_date
20130717
route
INTRAVENOUS
product_ndc
47848-045
application_number
NDA022468
labeler_name
AMRI Rensselaer, Inc.
spl_id
99d86f43-b4f7-4a7c-85c5-70b327880f5a
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_50683
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR